While low-dose aspirin may help prevent heart disease, a randomized, placebo-controlled study of almost 40,000 women finds that alternate day use of 100 mg aspirin for an average of 10 years does not lower the risk of total, breast, or colorectal cancer.
While low-dose aspirin may help prevent heart disease, a randomized, placebo-controlled study of almost 40,000 women finds that alternate day use of 100 mg aspirin for an average of 10 years does not lower the risk of total, breast, or colorectal cancer.
The study, which is the longest of any trial on this matter to be completed to date and which is part of the Women's Health Study, did show a trend toward reduction in the risk of lung cancer that was significant for lung cancer deaths, but the findings require confirmation.
Whether higher doses of aspirin confer protective benefits, as some previous studies have indicated, cannot be ruled out.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More